NCT06168786

Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRC

A Phase II, Single-arm, Open-label, Multi-Centers Study of Cadonilimab Combined With Fruquintinib and SBRT as A Third-line and Posterior Line Treatment in Patients With MSS Colorectal Cancer

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: Huazhong University of Science and Technology · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

A Phase II Study to Assess the Efficacy and Safety of Cadonilimab Combined With Fruquintinib and SBRT as A third-line and Posterior Line Treatment in Patients With MSS Colorectal Cancer

Conditions

• Colorectal Cancer

Interventions

Type	Name	Description
DRUG	Fruquintinib	Fruquintinib:5mg ,qd,po, d1-d14, q3w
DRUG	Cadonilimab	Cadonilimab:10mg/kg, ivgtt, d1, q3w
RADIATION	SBRT	SBRT:8-10Gy×5F，qod， in 10 days

Timeline

• Start date: 2023-06-20
• Primary completion: 2026-02-28
• Completion: 2027-02-28
• First posted: 2023-12-13
• Last updated: 2023-12-21

Locations

1 site across 1 country: China